Letters
Aspirin for everyone over 50?: Authors' reply
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7509.161-c (Published 14 July 2005) Cite this as: BMJ 2005;331:161
- Peter Elwood, chairman (pelwood@doctors.org.uk),
- Gareth Morgan, secretary,
- Ginevra Brown, statistician,
- Janet Pickering, statistician
- Welsh Aspirin Group, Department of Epidemiology, Statistics and Public Health, Cardiff University, Llandough Hospital, Penarth CF64 2XW
- Welsh Aspirin Group, Department of Epidemiology, Statistics and Public Health, Cardiff University, Llandough Hospital, Penarth CF64 2XW
EDITOR—The case for the wider use of aspirin in vascular prophylaxis arises from the belief that subjects should be empowered to make their own decision about protecting their own health. This will be achieved only if information on the risks and benefits of preventive measures, including low dose aspirin, is widely available.
Granted, the numerical risk-harm balance of aspirin in trials based …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.